A drop in vaccination turnout is driving concerns over vaccine expirations among members of the Moroccan Scientific Committee for Vaccination.
Morocco, as reported by Hespress EN back in November, has delayed multiple vaccine deliveries.
With its remaining threatened 4.5 million doses of Sinopharm, 3.6 million doses of Pfizer, and additional 4.2 million doses of COVAX vaccines, the country is still facing significant reluctance to reach its vaccination target.
According to Hespress AR, vaccine validity ranges from one to six months, prompting vaccination centers to use the vaccines that are closest to damage, to avoid running out of stocks and vaccine wastage.
Mustafa Al Naji, a member of the scientific committee, told Hespress AR that if the drop in vaccination continues, people will no longer be guaranteed protection,” as Morocco will have to find new financial resources for the acquisition of newer vaccines.
Despite the grim picture, the launch of the domestic vaccine manufacturing project is expected to kickstart in December.
Manufacturing is planned to launch at the end of December, with the syringing and eventual manufacturing of the Chinese Sinopharm vaccine.
Through the project, under Moroccan pharmaceuticals manufacturer Sothema, Moroccan health authorities are hoping to avoid the risk of vaccine damage and to be able to export all vaccine surplus to avoid expiration risks.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.